# Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

> **NCT01996267** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 437 (actual)

## Conditions studied

- Breast Cancer
- HER2 Positive

## Interventions

- **DRUG:** PTC+Pertuzumab
- **DRUG:** FEC-T+Pertuzumab

## Key facts

- **NCT ID:** NCT01996267
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-12
- **Primary completion:** 2018-12
- **Final completion:** 2030-12
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996267, "Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01996267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*